A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05566093` - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors	N/A
Completed	`NCT00970970` - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Recruiting	`NCT05568017` - Neoadjuvant PRRT With Y-90-DOTATOC in pNET	Phase 2
Not yet recruiting	`NCT06024343` - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction	N/A
Recruiting	`NCT03891784` - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors	Phase 2
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Recruiting	`NCT05997056` - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors	Phase 2
Not yet recruiting	`NCT06158516` - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors	Phase 2
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05040360` - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00576680` - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05610826` - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver	Phase 1/Phase 2
Active, not recruiting	`NCT03074513` - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	Phase 2
Completed	`NCT03967951` - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Not yet recruiting	`NCT03435770` - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms	N/A
Recruiting	`NCT04134832` - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting	`NCT05554744` - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors	N/A
Completed	`NCT02159989` - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Not yet recruiting	`NCT06406387` - ATRX/DAXX in EUS-FNB Specimens of Pan-NETs

NCT number	NCT03204019
Study type	Interventional
Source	Chinese Academy of Medical Sciences
Contact	Yihebali Chi, doctor
Email	dryihebalichi@126.com
Status	Recruiting
Phase	Phase 2
Start date	October 2016
Completion date	September 2018

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms